About

Motilent's Story

Motilent, a leading innovator in the field of gastroenterology, originated from the scientific curiosity and passion of its founder, Alex Menys PhD, MRes, AKC. 

Motilent focuses on assessing treatment response in Inflammatory Bowel Disease while actively engaging in a wide range of projects related to various gastrointestinal conditions such as constipation, gastroparesis, IBS, and other ailments featuring GI symptoms. 

Founded with the purpose of translating these advanced technologies into practical applications, Motilent remains deeply committed to conducting groundbreaking research in collaboration with esteemed international partners and is particularly enthusiastic about the potential of non-invasive gastroenterology technologies, including MRI, ultrasound, and capsule endoscopy. 

Motilent's culture is shaped by its fundamental beliefs, refined through experience. One core belief is the importance of real-world evidence, which guides the prompt and safe deployment of emerging technologies. By prioritising tangible evidence, Motilent ensures that these technologies reach end-users effectively. This approach strengthens their commitment to bridging the gap between technological advancements and practical applications, making a positive impact in the healthcare industry. 

Motilent's journey has made significant strides in transforming how the academic, life sciences, and clinical communities perceive the intricacies of the gastrointestinal system - committed to its ongoing mission -

'Changing the way we see the gut'.